NCT02419313View on ClinicalTrials.gov

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
ParkinsonTremor
Interventions
DRUG

incobotulinumtoxinA

Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.

DRUG

Saline

same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.

Trial Locations (1)

06520

Yale Neurology, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT02419313 - Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach | Biotech Hunter | Biotech Hunter